EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol

ESMO Gastrointestinal Oncology Pub Date : 2024-07-10 DOI:10.1016/j.esmogo.2024.100071

A. Petrillo , L. Oudijk , R. Sundar , C. Daumer , J. Casas , D. D’Haese , M. Mauer , N. van Grieken , E.C. Smyth , M. Moehler

{"title":"EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol","authors":"A. Petrillo , L. Oudijk , R. Sundar , C. Daumer , J. Casas , D. D’Haese , M. Mauer , N. van Grieken , E.C. Smyth , M. Moehler","doi":"10.1016/j.esmogo.2024.100071","DOIUrl":null,"url":null,"abstract":"<div><p>The evaluation of programmed death-ligand 1 (PD-L1) expression and the methodology employed are central to identify suitable candidates for immunotherapy among patients with gastro-oesophageal cancer (GC). Yet, there are no comprehensive global studies comparing the various methods and antibodies utilized for assessing PD-L1 positivity in GC. The ASPIRE study, led by the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Group (EORTC GITCG) and the National University Health System, Singapore, seeks to standardize the assessment of PD-L1 expression in GC. By comparing various PD-L1 scoring systems and assays, the study aims to simplify and harmonize the quantification and qualification of PD-L1 expression. Ultimately, this effort aims to facilitate the translation of endpoints in companion diagnostic settings. Here, we report the protocol of the study.</p></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"5 ","pages":"Article 100071"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949819824000323/pdfft?md5=192750832592e53e8be47e2b89f0a0b5&pid=1-s2.0-S2949819824000323-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Gastrointestinal Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949819824000323","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The evaluation of programmed death-ligand 1 (PD-L1) expression and the methodology employed are central to identify suitable candidates for immunotherapy among patients with gastro-oesophageal cancer (GC). Yet, there are no comprehensive global studies comparing the various methods and antibodies utilized for assessing PD-L1 positivity in GC. The ASPIRE study, led by the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Group (EORTC GITCG) and the National University Health System, Singapore, seeks to standardize the assessment of PD-L1 expression in GC. By comparing various PD-L1 scoring systems and assays, the study aims to simplify and harmonize the quantification and qualification of PD-L1 expression. Ultimately, this effort aims to facilitate the translation of endpoints in companion diagnostic settings. Here, we report the protocol of the study.

Abstract Image

查看原文本刊更多论文

EORTC 胃癌 PD-L1 生物标志物欧洲倡议：ASPIRE 研究方案

评估程序性死亡配体 1（PD-L1）的表达和所采用的方法是确定胃食管癌（GC）患者免疫疗法合适候选者的关键。然而，目前还没有全面的全球性研究对用于评估胃食管癌 PD-L1 阳性的各种方法和抗体进行比较。由欧洲癌症研究和治疗组织胃肠道小组（EORTC GITCG）和新加坡国立大学卫生系统领导的 ASPIRE 研究旨在规范 GC 中 PD-L1 表达的评估。通过比较各种 PD-L1 评分系统和检测方法，该研究旨在简化和统一 PD-L1 表达的量化和鉴定。最终，这项工作旨在促进终点在辅助诊断中的转化。在此，我们报告该研究的方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ESMO Gastrointestinal Oncology

自引率

0.00%

发文量